Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a strategic collaboration with ...

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

For Research Use Only. Not for use in diagnostic procedures. The purification of plasmid DNA (pDNA) is essential in molecular biology research. Over the years, plasmid DNA isolation technology has ...

SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development and ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Adeno-associated viral vectors (AAV vectors) are essential tools for delivering gene therapy to patients and are usually manufactured using plasmid-based approaches. However, there are challenges with ...

ZHENJIANG, China, Dec. 7, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio ...

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- The "CRISPR Technology Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.